# Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

> **NCT00875745** · PHASE1 · COMPLETED · sponsor: **Indiana University** · enrollment: 15 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute
- Leukemia, Promyelocytic, Acute
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Sorafenib-Vorinostat

## Key facts

- **NCT ID:** NCT00875745
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-05
- **Final completion:** 2013-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2014-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00875745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00875745, "Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00875745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*